Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Sparing Anti-Bacterial Prophylaxis in Acute Myeloid Leukemia during Post Induction Aplasia Does Not Impact on Bacteriemiae Incidence and Early Death: A Retrospective Single Center Study

Chiara Frairia, MD, Irene Urbino, MD, Ernesta Audisio, MD, Semra Aydin, MD PhD, Stefano D'Ardia, MD, Messa Emanuela, MD, Giorgia Iovino, MD, Barbara Nicolino, MD, Umberto Vitolo

Blood (2018) 132 (Supplement 1): 4001.

https://doi.org/10.1182/blood-2018-99-117222

Published: 2018

Journal Articles

Clinical Significance of Arbekacin Sulfate for High-Risk Infections Among Patients with Hematological Malignancies

Katsuhiro Miura, MD, Satomi Kiso, MD, Masaru Nakagawa, MD, Hiromichi Takahashi, MD PhD, Yoshito Uchino, MD, Hitomi Kodaira, MD, Noriyoshi Iriyama, MD PhD, Masashi Sakagami, MD, Shimon Ohtake, MD, Sumiko Kobayashi, MD PhD, Atsuko Hojo, MD, Mai Yagi, MD, Daisuke Kurita, MD, Yujin Kobayashi, MD PhD, Machiko Kusuda, MD, Yukio Hirabayashi, MD PhD, Yoshihiro Hatta, MD PhD, Masami Takei, MD PhD

Blood (2014) 124 (21): 3674.

https://doi.org/10.1182/blood.V124.21.3674.3674

Published: 2014

Journal Articles

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Todd Rosenblat, MD, Mark L. Heaney, MD PhD, Joseph G Jurcic, MD, Azra Raza, MD, John G. Mears, MD, Ruth Santos, BS, Diana Carrillo, BS, David Shum, MS, Jacquelyn Gonzales, BSN, RN, Kevin Zikaras, BS, Martin Santos, BS, Rong Zhang, MS, Glorymar Ibanezs, MS, Leah Hogdal, BA, Jennifer Crombie, MD, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony G. Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2014) 124 (21): 974.

https://doi.org/10.1182/blood.V124.21.974.974

Published: 2014

Journal Articles

A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy

Courtney D. DiNardo, MD, Fleur M. Aung, MD, Fernando Martinez, MD MPH, Naval Daver, MD, Tapan Kadia, MD, Nitin Jain, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Virgil M Reddy, MBBS, Guillermo Garcia-Manero, MD, Jorge Cortes, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Benjamin Lichtiger, MDPhD, Emil J. Freireich, MD

Blood (2014) 124 (21): 1564.

https://doi.org/10.1182/blood.V124.21.1564.1564

Published: 2014

Journal Articles

A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma

Tzu-Fei Wang, MD, Mark A. Fiala, BS, CCRP, Ningying Wu, PhD, Theresa Fletcher, Camille N. Abboud, MD, Amanda F. Cashen, MD, John F. Dipersio, MD, PhD, Geoffrey L. Uy, MD, Peter Westervelt, MD, PhD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MD

Blood (2013) 122 (21): 5492.

https://doi.org/10.1182/blood.V122.21.5492.5492

Published: 2013

Journal Articles

Successful Engrafment After HLA Identical Granulocyte Transfusion As Support Therapy in a Septic Shock Patient with Acute Lymphoblastic Leukemia

Roberto Ovilla, MD, Claudia Barrera-Carmona, MD, Nicolas Guzman-Bouilloud, MD, Elizabeth Buganza-Torio, MD, Rosa Jimenez-Alvarado, MD, Claudia Monreal-Alcantara, MD

Blood (2012) 120 (21): 4507.

https://doi.org/10.1182/blood.V120.21.4507.4507

Published: 2012

Journal Articles

Continuous Infusion Cyclophosphamide and Low Dose Total Body Irradiation (CICy/ldTBI) As a Conditioning Regimen for Tandem Autologous Transplant in Multiple Myeloma

Michael T. Byrne, DO, John R. Wingard, MD, Helen Leather, BPharm, Jan S Moreb, MD

Blood (2012) 120 (21): 4524.

https://doi.org/10.1182/blood.V120.21.4524.4524

Published: 2012

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Richard F. Schlenk, MD, Jürgen Krauter, MD, Markus Schaich, MD, Didier Bouscary, MD, PhD, Hervé Dombret, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Anita Zahlten, PhD, Lu Wang, PhD, Oliver G. Ottmann, MD, PhD

Blood (2011) 118 (21): 423.

https://doi.org/10.1182/blood.V118.21.423.423

Published: 2011

Journal Articles

Baseline Serum Ferritin Predicts Rate of Infection in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Gloria Mattiuzzi, MD, Hesham M. Amin, MD, MSC, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD

Blood (2009) 114 (22): 1611.

https://doi.org/10.1182/blood.V114.22.1611.1611

Published: 2009

Journal Articles

Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).

Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD, Stefan Faderl, MD, Jorge Cortes, MD, Zeev Estrov, MD, Patricia Boone, RN, Iain Stuart, MD, Robert Westwood, MD, Simon Green, MD, Judy H. Chiao, MD, Willilam Plunkett, PhD

Blood (2007) 110 (11): 884.

https://doi.org/10.1182/blood.V110.11.884.884

Published: 2007

Journal Articles

A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies.

David A. Rizzieri, William Tse, Khuda D. Khan, Anjali Advani, Jon Donze, Verena Karsten, Robert B. Geller, Stanton L. Gerson

Blood (2006) 108 (11): 1971.

https://doi.org/10.1182/blood.V108.11.1971.1971

Published: 2006

Journal Articles

Vancomycin Resistant Enterococcus as a Leading Cause of Early Infection-Related Mortality in Older (≥ 60 Years) AML Patients Admitted to a Community Hospital for Standard Induction Chemotherapy.

Krystal L. Hicks, PharmD, BCOP, Lisette Breto, Pharm.D., Luke Halbur, MD

Blood (2006) 108 (11): 4541.

https://doi.org/10.1182/blood.V108.11.4541.4541

Published: 2006

Journal Articles

Phase I Study of Triapine® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS).

Karen W.L. Yee, MD, Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD, Deborah Thomas, MD, Stefan Faderl, MD, Ivan King, PhD, Susan M. O’Brien, MD, Mario Sznol, MD, Francis J. Giles, MD

Blood (2005) 106 (11): 4925.

https://doi.org/10.1182/blood.V106.11.4925.4925

Published: 2005

NARROW

Sparing Anti-Bacterial Prophylaxis in Acute Myeloid Leukemia during Post Induction Aplasia Does Not Impact on Bacteriemiae Incidence and Early Death: A Retrospective Single Center Study

Clinical Significance of Arbekacin Sulfate for High-Risk Infections Among Patients with Hematological Malignancies

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy

A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma

Successful Engrafment After HLA Identical Granulocyte Transfusion As Support Therapy in a Septic Shock Patient with Acute Lymphoblastic Leukemia

Continuous Infusion Cyclophosphamide and Low Dose Total Body Irradiation (CICy/ldTBI) As a Conditioning Regimen for Tandem Autologous Transplant in Multiple Myeloma

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Baseline Serum Ferritin Predicts Rate of Infection in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).

A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies.

Vancomycin Resistant Enterococcus as a Leading Cause of Early Infection-Related Mortality in Older (≥ 60 Years) AML Patients Admitted to a Community Hospital for Standard Induction Chemotherapy.

Phase I Study of Triapine® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only